Tag: Brian Hubbard

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

pharmanewsdaily- September 19, 2020

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More